Advertisement

Are There Differences in the Symptoms that Respond to a Selective Serotonin or Norepinephrine Reuptake Inhibitor?

      Background

      We examined two previously published studies comparing a norepinephrine (NE) selective agent, reboxetine, and a serotonin (5-HT) selective agent, fluoxetine, to determine if these agents have different effects on individual depressive symptoms.

      Methods

      Both studies were 8-week, double-blind, comparison studies of men and women with DSM III-R major depression. Within-group effect sizes for individual symptom change on the Hamilton Depression Rating Scale (HAMD) were determined in the observed case samples and in patients for whom the symptom was relatively severe at baseline. We required that any significant differences in one sample be cross-validated in the second.

      Results

      Two hundred fifty-three subjects in study I and 168 subjects in study II were randomized to reboxetine or fluoxetine. In both samples, depressed mood, decreased interest, and psychic anxiety had the greatest change. Effect sizes for all HAMD symptoms were similar for the two drugs. No difference between groups in one sample was replicated in the second. Among subjects with severe symptoms, no significant differences were cross-validated.

      Conclusions

      Reboxetine and fluoxetine appear to have similar effects on depressive symptoms. These data suggest that NE and 5-HT selective antidepressant drugs act through the same final common pathway and challenge the belief that symptom differences are useful for antidepressant selection.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aberg A.
        Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant.
        Acta Psychiatr Scand. 1981; 63: 244-255
        • Andreoli V.
        • Caillard V.
        • Deo R.S.
        • Rybakowski J.K.
        Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
        J Clin Psychopharmacol. 2002; 22: 393-399
        • Ascher J.A.
        • Cole J.O.
        • Colin J.N.
        • Feighner J.P.
        • Ferris R.M.
        • Fibiger H.C.
        • et al.
        Bupropion.
        J Clin Psychiatry. 1995; 56: 395-401
        • Ban T.A.
        • Gaszner P.
        • Aguglia E.
        • Batista R.
        • Castillo A.
        • Lipsey J.-P.
        • et al.
        Clinical efficacy of reboxetine.
        Hum Psychopharmacol. 1997; 13: S29-S39
        • Beasley C.M.
        • Sayler M.E.
        • Bosomworth J.C.
        • Wernicke J.F.
        High-dose fluoxetine.
        J Clin Psychopharmacol. 1991; 11: 166-174
        • Berman R.M.
        • Narasimhan M.
        • Miller H.L.
        • Anand A.
        • Cappiello A.
        • Oren D.A.
        • et al.
        Transient depressive relapse induced by catecholamine depletion.
        Arch Gen Psychiatry. 1999; 56: 395-403
        • Berzewski H.
        • Van Moffaert M.
        • Gagiano C.A.
        Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes.
        Eur Neuropsychopharmacol. 1997; 7: S37-S47
        • Bodkin J.A.
        • Lasser R.A.
        • Wines J.D.
        • Gardner D.M.
        • Baldessarini R.J.
        Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
        J Clin Psychiatry. 1997; 58: 137-145
        • Bondareff W.
        • Alpert M.
        • Friedhoff A.J.
        • Richter E.M.
        • Clary C.M.
        • Batzar E.
        • et al.
        Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life.
        Am J Psychiatry. 2000; 157: 729-736
        • Bouchard J.M.
        • Delaunay J.
        • Delisle J.-P.
        • Grasset N.
        • Mermberg P.F.
        • Molczadzki M.
        • et al.
        Citalopram versus maprotiline.
        Acta Psychiatr Scand. 1987; 76: 583-592
        • Bowden C.L.
        • Schatzberg A.F.
        • Rosenbaum A.
        • Contreras S.A.
        • Samson J.A.
        • Dessain E.
        • et al.
        Fluoxetine and desipramine in major depressive disorder.
        J Clin Psychopharmacol. 1993; 13: 305-310
        • Bremner J.D.
        • Innis R.B.
        • Salomon R.M.
        • Staib L.H.
        • Ng C.K.
        • Miller H.L.
        • et al.
        Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse.
        Arch Gen Psychiatry. 1997; 54: 364-374
        • Bremner J.D.
        • Vythilingam M.
        • Ng C.K.
        • Vermetten E.
        • Nazeer A.
        • Oren D.A.
        • et al.
        Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms.
        JAMA. 2003; 289: 3125-3134
        • Burns R.A.
        • Lock T.
        • Edwards D.R.L.
        • Katona C.L.E.
        • Harrison D.A.
        • Robertson M.M.
        • et al.
        Research report.
        J Affect Disord. 1995; 35: 97-106
        • Cohen J.
        Statistical Power Analysis for the Behavioral Sciences.
        2nd ed. Erlbaum, Hillsdale, NJ1988
        • deJonghe F.
        • Ravelli D.P.
        • Tuynmna-Qua H.
        A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.
        Pharmacopsychiatry. 1991; 24: 62-67
        • deJonghe F.
        • Swinkels J.
        • Tuynmna-Qua H.
        Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression.
        Pharmacopsychiatry. 1991; 24: 21-27
        • Delgado P.L.
        • Charney D.S.
        • Price L.H.
        • Aghajanian G.K.
        • Landis H.
        • Heninger G.R.
        • et al.
        Serotonin function and the mechanism of antidepressant action.
        Arch Gen Psychiatry. 1990; 47: 411-418
        • Dubini A.
        • Dose M.
        • Polin V.
        Do noradrenaline and serotonin differentially affect social motivation and behavior?.
        Eur Neuropsychopharmacol. 1997; 7: S49-S55
        • Dubovsky S.L.
        Beyond the serotonin reuptake inhibitors.
        J Clin Psychiatry. 1994; 55: 34-44
        • Fabre L.F.
        • Scharf M.B.
        • Itil T.M.
        Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression.
        J Clin Psychiatry. 1991; 52: 62-67
        • Filteau M.J.
        • Baruch P.
        • Lapierre Y.
        • Bakish D.
        • Blanchard A.
        SSRIs in anxious-agitated depression.
        Int Clin Psychopharmacol. 1995; 10: 51-54
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Hamilton M.
        Development of a rating scale for primary depressive illness.
        Br J Soc Clin Psychol. 1967; 6: 278-296
        • Hamilton M.
        Rating depressive patients.
        J Clin Psychiatry. 1980; 41: 21-24
        • Healy D.
        • McMonagle T.
        The enhancement of social functioning as a therapeutic principle in the management of depression.
        J Psychopharmacol. 1997; 11: S25-S31
        • Joyce P.R.
        • Paykel E.S.
        Predictors of drug response in depression.
        Arch Gen Psychiatry. 1989; 46: 89-99
        • Knutson B.
        • Wolkowitz O.M.
        • Cole S.W.
        • Chan T.
        • Moore E.A.
        • Johnson R.C.
        • et al.
        Selective alteration of personality and social behavior by serotonergic intervention.
        Am J Psychiatry. 1998; 155: 373-379
        • Learned-Coughlin S.M.
        • Bergstrom M.
        • Savitcheva I.
        • Ascher J.
        • Schmith V.D.
        • Langstrom B.
        In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography.
        Biol Psychiatry. 2003; 54: 800-805
        • Leon A.C.
        • Shear M.K.
        • Portera L.
        • Klerman G.L.
        Effect size as a measure of symptom-specific change in clinical trials.
        Psychopharmacol Bull. 1993; 29: 163-167
        • Maas J.W.
        • Fawcett J.
        • Dekirmanjian H.
        3-Methoxy-phenylglycol (MHPG) excretion in depressive states. A pilot study.
        Arch Gen Psychiatry. 1968; 19: 129-134
        • Maas J.W.
        • Koslow S.H.
        • Katz M.M.
        • Bowden C.L.
        • Gibbons R.L.
        • Stokes P.E.
        • et al.
        Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs.
        Am J Psychiatry. 1984; 141: 1159-1171
        • Massana J.
        • Moller H.-J.
        • Burrows G.D.
        • Montenegro R.M.
        Reboxetine.
        Int Clin Psychopharmacol. 1999; 14: 73-80
        • Mazure C.
        • Nelson J.C.
        • Price L.H.
        Reliability and validity of the symptoms of major depressive illness.
        Arch Gen Psychiatry. 1986; 43: 451-456
        • Miller H.L.
        • Delgado P.
        • Salomon R.
        • Berman R.
        • Krystal J.H.
        • Heninger G.R.
        • et al.
        Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.
        Arch Gen Psychiatry. 1996; 53: 117-128
        • Montgomery S.A.
        Is there a role for a pure noradrenergic drug in the treatment of depression?.
        Eur Neuropsychopharmacol. 1997; 7: S3-S9
        • Montgomery S.A.
        Selective serotonin reuptake inhibitors in the acute treatment of depression.
        in: Bloom F.E. Kupfer D.J. Psychopharmacology The Fourth Generation of Progress. Raven Press, Ltd, New York1995
        • Montgomery S.A.
        The efficacy of fluoxetine as an antidepressant in the short and long term.
        Int Clin Psychopharmacol. 1989; 4: 113-119
        • Montgomery S.A.
        • James D.
        • Montgomery D.B.
        Pharmacological specificity is not the same as clinical selectivity.
        Psychopharmacology (Berl). 1987; 3: 179-183
        • Moon C.
        Treatment of major depression in general practice.
        Br J Clin Pract. 1990; 50: 240-244
        • Nelson J.C.
        Synergistic benefits of serotonin and noradrenaline reuptake inhibition.
        Depress Anxiety. 1998; 7: 5-6
        • Nelson J.C.
        A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression.
        Biol Psychiatry. 1999; 46: 1301-1308
      1. Nelson JC (in press): The clinical role of norepinephrine antidepressants in depression and anxiety disorders. In: Ordway GA, Frazer A, Schwartz M, editors. Norepinephrine: Neurobiology and Therapeutics. Cambridge, UK: Cambridge University Press.

        • Nelson J.C.
        • Charney D.S.
        The symptoms of major depressive illness.
        Am J Psychiatry. 1981; 138: 1-12
      2. Nelson JC, Clary CM, Leon AC, Schneider LS (in press): Symptoms of late life depression: Frequency and change during treatment. Am J Geriatr Psychiatry.

        • Nelson J.C.
        • Kennedy J.S.
        • Pollock B.G.
        • Laghrissi-Thode F.
        • Narayan M.
        • Nobler M.S.
        • et al.
        Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease.
        Am J Psychiatry. 1999; 156: 1024-1028
        • Nelson J.C.
        • Mazure C.M.
        • Jatlow P.I.
        • Bowers Jr, M.B.
        • Price L.H.
        Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression.
        Biol Psychiatry. 2004; 55: 296-300
        • Nelson J.C.
        • Mazure C.
        • Quinlan D.M.
        • Jatlow P.
        Drug responsive symptoms in melancholia.
        Arch Gen Psychiatry. 1984; 41: 663-668
        • Petersen T.
        • Dording C.
        • Neault N.B.
        • Kornbluh R.
        • Alpert J.E.
        • Nierenberg A.A.
        • et al.
        A survey of prescribing practices in the treatment of depression.
        Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26: 177-187
        • Poelinger W.
        • Haber H.
        Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of outpatients with depressive disorders.
        Int Clin Psychopharmacol. 1989; 4: 47-50
        • Pollock B.G.
        • Ferrell R.E.
        • Mulsant B.H.
        • Mazumdar S.
        • Miller M.
        • Sweet R.A.
        • et al.
        Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.
        Neuropsychopharmacology. 2000; 23: 587-590
        • Rampello L.
        • Chiechio S.
        • Nicoletti G.
        • Alvano A.
        • Vecchio I.
        • Raffaele R.
        • et al.
        Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
        Psychopharmacology (Berl). 2004; 173: 73-78
        • Raskin A.
        • Schulterbrandt J.G.
        • Reatig N.
        • McKeon J.J.
        Differential response to chlorpromazine, imipramine, and placebo.
        Arch Gen Psychiatry. 1970; 23: 164-173
        • Riva M.
        • Brunello N.
        • Rovescalli A.C.
        • Galimberti R.
        • Carfagna N.
        • Carmininati P.
        • et al.
        Effect of reboxetine, a new antidepressant drug on the central noradrenergic system.
        J Drug Dev. 1989; 1: 243-254
        • Robertson M.M.
        • Abou-Saleh M.T.
        • Harrison D.A.
        • Nairac B.L.
        • Edwards D.R.L.
        • Lock T.
        • et al.
        A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness.
        J Psychopharmacol. 1994; 8: 98-103
        • Roth D.
        • Mattes J.
        • Sheehan H.
        • Sheehan D.V.
        A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression.
        Prog Neuropsychopharmacol Biol Psychiatry. 1990; 4: 929-939
        • Rush A.J.
        • Batey S.R.
        • Donahue R.M.J.
        • Ascher J.A.
        • Carmody T.
        • Metz A.
        Does pretreatment anxiety predict response to either bupropion SR or sertraline?.
        J Affect Disord. 2001; 64: 81-87
        • Rush A.J.
        • Trivedi M.H.
        • Carmody T.J.
        • Donahue R.M.J.
        • Houser T.L.
        • Bolden-Watson C.
        • et al.
        Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline.
        Neuropsychopharmacology. 2001; 25: 131-138
        • Simon G.E.
        • Heiligenstein J.H.
        • Grothaus L.
        • Katon W.
        • Revicki D.
        Should anxiety and insomnia influence antidepressant selection.
        J Clin Psychiatry. 1998; 59: 49-55
        • Smeraldi E.
        • Zanardi R.
        • Benedetti F.
        • Di Bella D.
        • Perez J.
        • Catalano M.
        Polymorphism with the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.
        Mol Psychiatry. 1998; 3: 508-511
        • Trivedi M.H.
        • Rush A.J.
        • Carmody T.J.
        • Donahue R.M.
        • Bolden-Watson C.
        • Houser T.L.
        • et al.
        Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?.
        J Clin Psychiatry. 2001; 62: 776-781
        • Versiani M.
        • Amin M.
        • Chouinard G.
        Double-blind, placebo-controlled study with reboxetine in inpatints with severe major depressive disorder.
        J Clin Psychopharmacol. 2000; 20: 28-34
        • Zald D.H.
        • Depue R.A.
        Serotonergic functioning correlates with positive and negative affect in psychiatrically healthy males.
        Pers Indiv Dif. 2001; 30: 71-86
        • Zanardi R.
        • Benedetti F.
        • Di Bella D.
        • Catalano M.
        • Smeraldi E.
        Efficacy of paroxetine in depression is influenced by a functional polymorphism with the promoter of the serotonin transporter gene.
        J Clin Psychopharmacol. 2000; 20: 105-107
        • Zimmerman M.
        • Posternak M.
        • Friedman M.
        • Attiullah N.
        • Baymiller S.
        • Boland R.
        • et al.
        Which factors influence psychiatrists’ selection of antidepressants?.
        Am J Psychiatry. 2004; 161: 1285-1289